About Us

Akiram Therapeutics is a Swedish biotech company based on front-line research at Uppsala University. We develop targeted radioimmunotherapy for cancer, designed to deliver radioactivity directly to cancer cells while sparing normal tissues. The company’s focus is to create a treatment for cancers where no effective therapies are available today.

Our Story

Akiram Therapeutics was founded by three partners, covering complementing experience: Professor Marika Nestor, the principal investigator with profound knowledge in the target biology and radiation sciences; Assistant Professor Anja Mortensen bringing competence in pharmacology and translational oncology; and Adjunct Professor Fredrik Frejd with 20 years of industrial experience in preclinical and clinical development of targeted therapeutics. The founders have generated more than 150 publications in peer-reviewed journals.

Vision

The vision of Akiram Therapeutics is to develop more effective treatments with fewer side effects for cancer patients, particularly those with limited or no available treatment options.

Mission

To provide tumor-targeting radiotherapeutic treatments to cancer patients, utilizing the company’s proprietary research findings and antibody product.